These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 22494563)

  • 21. Evolution of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases: 8-Year Single-Institutional Experience.
    Narasimhan V; Britto M; Pham T; Warrier S; Naik A; Lynch AC; Michael M; Tie J; Ramsay R; Heriot A
    Dis Colon Rectum; 2019 Oct; 62(10):1195-1203. PubMed ID: 31490828
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study.
    Glehen O; Kwiatkowski F; Sugarbaker PH; Elias D; Levine EA; De Simone M; Barone R; Yonemura Y; Cavaliere F; Quenet F; Gutman M; Tentes AA; Lorimier G; Bernard JL; Bereder JM; Porcheron J; Gomez-Portilla A; Shen P; Deraco M; Rat P
    J Clin Oncol; 2004 Aug; 22(16):3284-92. PubMed ID: 15310771
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cytoreductive surgery and intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis: prognosis and treatment of recurrences in a cohort study.
    Cashin PH; Graf W; Nygren P; Mahteme H
    Eur J Surg Oncol; 2012 Jun; 38(6):509-15. PubMed ID: 22475555
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High-grade postoperative complications affect survival outcomes of patients with colorectal Cancer peritoneal metastases treated with Cytoreductive surgery and Hyperthermic Intraperitoneal chemotherapy.
    Zhou S; Feng Q; Zhang J; Zhou H; Jiang Z; Liu Z; Zheng Z; Chen H; Wang Z; Liang J; Pei W; Liu Q; Zhou Z; Wang X
    BMC Cancer; 2021 Jan; 21(1):41. PubMed ID: 33413223
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cytoreductive surgery and hyperthermic intraperitenoal chemotherapy (HIPEC) for colorectal and appendiceal carcinomas with peritoneal carcinomatosis.
    Pallas N; Karamveri C; Kyziridis D; Hristakis C; Kyriakopoulos V; Kalakonas A; Vaikos D; Tentes AK
    J BUON; 2017; 22(6):1547-1553. PubMed ID: 29332351
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of patient selection policy and pattern of recurrence after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal carcinomatosis.
    Robella M; Vaira M; Borsano A; DE Simone M
    Minerva Chir; 2018 Apr; 73(2):133-141. PubMed ID: 29397633
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis.
    Franko J; Ibrahim Z; Gusani NJ; Holtzman MP; Bartlett DL; Zeh HJ
    Cancer; 2010 Aug; 116(16):3756-62. PubMed ID: 20564081
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 201 consecutive cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) procedures in a single Asian tertiary centre.
    Tan G; Chia C; Kumar M; Choo SP; Chia J; Tham CK; Chua C; Soo KC; Teo M
    Int J Hyperthermia; 2017 May; 33(3):288-294. PubMed ID: 27855557
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastasis in Norway: Prognostic factors and oncologic outcome in a national patient cohort.
    Frøysnes IS; Larsen SG; Spasojevic M; Dueland S; Flatmark K
    J Surg Oncol; 2016 Aug; 114(2):222-7. PubMed ID: 27173150
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Iterative cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: A multi-institutional experience.
    Alzahrani NA; Valle SJ; Fisher OM; Sugarbaker PH; Yonemura Y; Glehen O; Goere D; Honore C; Brigand C; de Hingh I; Verwaal VJ; Deraco M; Baratti D; Kusamura S; Pocard M; Piso P; Maerz L; Marchal F; Moran B; Levine EA; Dumont F; Pezet D; Abboud K; Kozman MA; Liauw W; Morris DL;
    J Surg Oncol; 2019 Mar; 119(3):336-346. PubMed ID: 30554404
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety of intraperitoneal Mitomycin C versus intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis of colorectal cancer undergoing cytoreductive surgery and HIPEC.
    van Eden WJ; Kok NFM; Woensdregt K; Huitema ADR; Boot H; Aalbers AGJ
    Eur J Surg Oncol; 2018 Feb; 44(2):220-227. PubMed ID: 29258720
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Timing of Systemic Chemotherapy in Patients With Colorectal Peritoneal Carcinomatosis Treated With Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
    van Eden WJ; Kok NF; Jóźwiak K; Lahaye ML; Beets GL; van Leerdam ME; Boot H; Aalbers AG
    Dis Colon Rectum; 2017 May; 60(5):477-487. PubMed ID: 28383447
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neoadjuvant chemotherapy with bevacizumab may improve outcome after cytoreduction and hyperthermic intraperitoneal chemoperfusion (HIPEC) for colorectal carcinomatosis.
    Ceelen W; Van Nieuwenhove Y; Putte DV; Pattyn P
    Ann Surg Oncol; 2014 Sep; 21(9):3023-8. PubMed ID: 24756812
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Colorectal peritoneal carcinomatosis treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: the experience of a tertiary Asian center.
    Teo MC; Ching Tan GH; Lim C; Chia CS; Tham CK; Soo KC
    Asian J Surg; 2015 Apr; 38(2):65-73. PubMed ID: 25059814
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cytoreductive surgery and perioperative intraperitoneal chemotherapy for isolated colorectal peritoneal carcinomatosis: experimental therapy or standard of care?
    Yan TD; Morris DL
    Ann Surg; 2008 Nov; 248(5):829-35. PubMed ID: 18948811
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Peritoneal carcinomatosis index predicts survival in colorectal patients undergoing HIPEC using oxaliplatin: a retrospective single-arm cohort study.
    Burnett A; Lecompte MA; Trabulsi N; Dubé P; Gervais MK; Trilling B; Cloutier AS; Sideris L
    World J Surg Oncol; 2019 May; 17(1):83. PubMed ID: 31092250
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) delivered via a modified perfusion system for peritoneal carcinomatosis of colorectal origin.
    Cravioto-Villanueva A; Cavazos M; Luna-Perez P; Martinez-Gomez H; Ramirez ML; Solorzano J; Montiel H; Esquivel J
    Surg Today; 2016 Aug; 46(8):979-84. PubMed ID: 27138212
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Results of two bi-institutional prospective studies using intraperitoneal oxaliplatin with or without irinotecan during HIPEC after cytoreductive surgery for colorectal carcinomatosis.
    Quenet F; Goéré D; Mehta SS; Roca L; Dumont F; Hessissen M; Saint-Aubert B; Elias D
    Ann Surg; 2011 Aug; 254(2):294-301. PubMed ID: 21772129
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of prognostic scores for patients with colorectal cancer peritoneal metastases treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Cashin PH; Graf W; Nygren P; Mahteme H
    Ann Surg Oncol; 2013 Dec; 20(13):4183-9. PubMed ID: 23975316
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of peritoneal carcinomatosis from colonic cancer by cytoreduction, peritonectomy and HIPEC: preliminary results in highly selected patients.
    Robella M; Vaira M; Marsanic P; Mellano A; Cinquegrana A; Sottile A; De Simone M
    Minerva Chir; 2013 Dec; 68(6):551-8. PubMed ID: 24193287
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.